Program Director, Ethical and Regulatory Affairs, Division of Cancer Treatment and Diagnosis
National Cancer Institute
Carol Juliet Weil, JD, is a program director for ethical and regulatory affairs at the National Cancer Institute (NCI) and an expert in research protections pertaining to the collection, storage, and downstream uses of biological samples and genomic and clinical data. Ms. Weil oversees the ethical, legal, and social implications of cancer research in the NCI’s Cancer Diagnosis Program including policies on consent, data sharing, biospecimen governance, community engagement, and disclosure of research results and incidental findings. She facilitates the development of embedded bioethics protocols in NCI's precision medicine oncology trials, including surveys about tissue donation and genetic counseling pilots for returning genomic findings. She has been a non-scientist member of the NCI IRB since 2012 and now serves on the NIH IRB. Primary author publications include: "Mandating General Consent for Use of Biospecimens in Research: A Call for Enhanced Community Engagement" , book chapter in The Future of Human Subjects Research Regulation, Perspectives on the Future edited by I. Glenn Cohen and Holly Fernandez Lynch (MIT Press 2014), and "NCI Think Tank Concerning the Identifiability of Biospecimens and 'Omic Data" in Genetics in Medicine (2013). She is currently co-authoring a chapter on genomics research in the third edition of IRB Management and Function, to be published by Jones and Bartlett in 2020. Ms. Weil has been a member of the AER Core Conference Planning Committee for three years.
Tuesday, November 19
10:15 AM – 11:30 AM
Tuesday, November 19
3:45 PM – 5:00 PM
Wednesday, November 20
10:00 AM – 11:15 AM